Non-Hodgkin Lymphoma: Diagnosis and Treatment

Ansell, Stephen M.; Armitage, James
August 2005
Mayo Clinic Proceedings;Aug2005, Vol. 80 Issue 8, p1087
Academic Journal
Non-Hodgkin lymphomas are a heterogeneous group of malignancies of the lymphoid system. Based on the World Health Organization classification of hematological and lymphoid tumors, these diseases have been classified as B-cell and T-cell neoplasms. B-cell lymphomas account for approximately 90% of all lymphomas, and the 2 most common histological disease entities are follicular lymphoma and diffuse large B-cell lymphoma. Approximately 55,000 to 60,000 new cases of non-Hodgkin lymphoma are diagnosed annually in the United States, a number that has nearly doubled during the past 3 decades. The Ann Arbor Staging Classification is used routinely to classify the extent of disease, and the international Prognostic Index has been used to define prognostic subgroups. Also, recent data have Identified molecular and genetic markers of prognosis that may be used In the future to further refine treatment decisions. Treatment of these diseases is based on the histology and extent of disease. Patients with follicular lymphomas with early-stage disease generally are treated with radiation therapy, whereas those with stage ill and IV disease requiring treatment usually are treated with chemotherapy, immunotherapy, or radioimmunotherapy. These patients generally experience long survival, but only a minority are cured. For patients with diffuse large B-cell lymphoma, treatment of limited-stage disease generally includes doxorubicin-based chemotherapy combined with rituximab followed by involved field radiation therapy. Those with extensive disease are treated with rituximab combined with chemotherapy alone. Disease relapse is a problem, and high-dose therapy with stem cell support is the treatment of choice for chemosensitive relapsed aggressive lymphomas. Patients with chemoresistant disease or whose disease relapses subsequently should be treated with novel experimental therapies.


Related Articles

  • Lymphoma in the immunocompromised. Sita-Lumsden, Ailsa; Harris, Philippa; Bower, Mark // British Journal of Hospital Medicine (17508460);May2010, Vol. 71 Issue 5, p264 

    The article discusses the differences on the clinical management of lymphomas in Great Britain. It primarily focuses on the characteristics and development on the two forms of acquired lyphomas, the congenital immunodeficiency and lymphoproliferative disorders. Specifically, it examines the...

  • Potential therapeutic strategy for non-Hodgkin lymphoma by anti-CD20scFvFc/CD28/CD3zeta gene tranfected T cells. Yihu Zheng; Kang Yu; Jimei Du; Lei Jiang; Shenghui Zhang; Yixiang Han; Panpan Yu; Yingxia Tan // Journal of Experimental & Clinical Cancer Research (17569966);2010, Vol. 29, p121 

    Background: Anti-CD20 monoclonal antibody treatment has not only increased survival and cure rates in many non-Hodgkin lymphomas, but also has prompted an explosion in the development of novel antibodies and biologically active substances with specific cellular targets in the field of...

  • Attenuation of the epidemic increase in non-Hodgkin's lymphomas in Spain. Marcos-Gragera, R.; Pollán, M.; Chirlaque, M. D.; Gumà, J.; Sanchez, M. J.; Garau, I. // Annals of Oncology;May2010, Vol. 21 Issue suppl_3, piii90 

    Background: Attenuation of the epidemic increase in non-Hodgkin's lymphoma (NHL) incidence has recently been reported in the USA and Nordic European countries. After two decades of steadily increasing NHL, this study sought to ascertain whether a similar stabilisation might have taken place in...

  • High expression of Cathepsin D in Non-Hodgkin's Lymphomas negatively impacts on clinical outcome. Nicotra, Giuseppina; Manfroi, Federica; Follo, Carlo; Castino, Roberta; Fusco, Nicola; Peracchio, Claudia; Kerim, Simonetta; Valente, Guido; Isidoro, Ciro // Disease Markers;2010, Vol. 28 Issue 3, p167 

    The lysosomal protease Cathepsin D (CD) has been implicated in the homeostasis of lymphatic tissues. We investigated whether the level of CD expression influences the progression and the clinical outcome in Non-Hodgkin's Lymphomas (NHLs). The expression of CD was assessed by immunohistochemistry...

  • Two cases of sarcoidosis-lymphoma syndrome. Nada Suvajdzic; Branislava Milenkovic; Maja Perunicic; Jelena Stojsic; Snezana Jankovic // Medical Oncology;Dec2007, Vol. 24 Issue 4, p469 

    Abstract  An association between sarcoidosis and lymphoproliferative diseases (LD), the sarcoidosis-lymphoma syndrome, has been previously described, and may be attributed to the underlying immunological abnormalities that occur during the sarcoidosis disease process. We report two...

  • Sunlight May Reduce Risk for Some Cancers. Hogle, William P. // Clinical Journal of Oncology Nursing;Apr2005, Vol. 9 Issue 2, p146 

    Deals with a study which looks for links between sunlight exposure and several types of lymphomas. Result of a study of people living in Connecticut; Hypothesis about sunlight.

  • 18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Management of Aggressive Non-Hodgkin's B-Cell Lymphoma. Shelly, M. J.; McDermott, S.; O'Connor, O. J.; Blake, M. A. // ISRN Hematology;2012, p1 

    18-Fluorodeoxyglucose (FDG-PET/CT) is an established imaging modality that has been proven to be of benefit in the management of aggressive B-cell non-Hodgkin's lymphoma, such as diffuse large B-cell lymphoma and advanced stage follicular lymphoma. The combination of anatomic and functional...

  • Impact of PET on the Radiation Treatment of Hodgkin's Lymphoma. Versari, Annibale; Iotti, Cinzia; Merli, Francesco // Current Radiopharmaceuticals;Jul2009, Vol. 2 Issue 3, p169 

    Hodgkin's lymphoma (HL) is a lymphoproliferative malignancy that frequently affects young people. Because patients with HL are often cured, this neoplasm serves as a clinical laboratory for investigating the late effects of cancer therapy. The "hot" issues today are, in advanced stages, how to...

  • Primary breast lymphoma and HIV/AIDS. Barnardt, Pieter; Narinesingh, Dylan // Southern African Journal of HIV Medicine;Sep2011, Vol. 12 Issue 3, p21 

    Primary extranodal lymphoma of the breast is rare and accounts for 0.04 - 0.53% of all malignant tumours, less than 1% of non-Hodgkin's lymphomas (NHLs) and 1.7% of extranodal NHLs.1 Extranodal lymphoma arises from tissue other than lymph nodes and sites that normally contain no lymphoid tissue....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics